These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19137119)

  • 1. Lubiprostone--a novel treatment for irritable bowel syndrome with constipation.
    Owen RT
    Drugs Today (Barc); 2008 Sep; 44(9):645-52. PubMed ID: 19137119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Saad R; Chey WD
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):497-508. PubMed ID: 19072397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lubiprostone: RU 0211, SPI 0211.
    Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lubiprostone for constipation and irritable bowel syndrome with constipation.
    Tuteja AK; Rao SS
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lubiprostone: in constipation-predominant irritable bowel syndrome.
    Carter NJ; Scott LJ
    Drugs; 2009 Jun; 69(9):1229-37. PubMed ID: 19537839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
    Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
    Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone: chloride channel activator for chronic constipation.
    Rivkin A; Chagan L
    Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
    Drossman DA; Chey WD; Johanson JF; Fass R; Scott C; Panas R; Ueno R
    Aliment Pharmacol Ther; 2009 Feb; 29(3):329-41. PubMed ID: 19006537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
    Ginzburg R; Ambizas EM
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1091-7. PubMed ID: 18680443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
    Schey R; Rao SS
    Dig Dis Sci; 2011 Jun; 56(6):1619-25. PubMed ID: 21523369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
    Raschi E; De Ponti F
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):293-305. PubMed ID: 24387275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
    Johanson JF; Morton D; Geenen J; Ueno R
    Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
    Chang L; Chey WD; Drossman D; Losch-Beridon T; Wang M; Lichtlen P; Mareya S
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1114-1122. PubMed ID: 27669680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.